Diagnostic and Therapeutic Challenges in a Patient with Synchronous Very High-Risk Prostate Adenocarcinoma and Anal Carcinoma

Curr Oncol. 2022 Jan 15;29(1):377-382. doi: 10.3390/curroncol29010033.

Abstract

A 79-year-old HIV-negative Caucasian man with a medical history of smoking 20 pack-years (quit 40 years prior), early-stage non-small cell lung cancer status post-lobectomy 13 years earlier at an outside hospital without evidence of recurrence, and benign prostatic hypertrophy was diagnosed with synchronous very high-risk prostate adenocarcinoma and early-stage anal basaloid squamous cell carcinoma. He proceeded to undergo concurrent treatment for these tumors, consisting of androgen deprivation therapy, external beam radiation therapy, and a brachytherapy boost for the prostate adenocarcinoma; for the anal carcinoma, he was treated with definitive chemoradiation. Over 3.5 years since the completion of radiotherapy, he remains in clinical and biochemical remission.

Keywords: anal carcinoma; prostate adenocarcinoma; synchronous cancers.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Adenocarcinoma* / therapy
  • Aged
  • Androgen Antagonists / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / therapy
  • Humans
  • Lung Neoplasms* / drug therapy
  • Male
  • Prostate / pathology
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / therapy

Substances

  • Androgen Antagonists